Vertice Launches With Up To $300m For Specialty Pharma Deals
This article was originally published in Scrip
Executive Summary
While the big fish in the biopharma ocean are swallowing up all of the small fish, Vertice Pharma LLC is swimming against the tide with up to $300m from Warburg Pincus to support the startup's specialty pharmaceuticals strategy, starting with the acquisition of VistaPharm.